Protein profiling in hepatocellular carcinoma by label-free quantitative proteomics in two west african populations. by Fye, HK et al.
Protein Profiling in Hepatocellular Carcinoma by Label-
Free Quantitative Proteomics in Two West African
Populations
Haddy K. S. Fye1,3, Cynthia Wright-Drakesmith1, Holger B. Kramer1, Suzi Camey2,5, Andre Nogueira da
Costa2, Adam Jeng3, Alasana Bah3, Gregory D. Kirk4, Mohamed I. F. Sharif6, Nimzing G. Ladep6,
Edith Okeke8, Pierre Hainaut2,7, Simon D. Taylor-Robinson6, Benedikt M. Kessler1*, Maimuna E. Mendy2,3
1Nuffield Department of Medicine, Henry Wellcome Building for Molecular Physiology - University of Oxford, Oxford, Oxfordshire, United Kingdom, 2 Laboratory Services
and Bio-bank Group, International Agency for Research on Cancer, Lyon, France, 3Department of Disease Control and Elimination, MRC Unit (UK) The Gambia
Laboratories, Fajara, Banjul, The Gambia, 4Department of Epidemiology - Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United
States of America, 5Departamento de Estatistica, Instituto de Matematica, Universidade Federal do Rio Grande do Sul, Rio Grande, Brazil, 6 Liver Unit - Division of Diabetes
Endocrinology and Metabolism, Department of Medicine, Imperial College London, London, United Kingdom, 7 The International Prevention Research Institute, Lyon,
France, 8 Jos University Teaching Hospital, Jos, Plateau State, Nigeria
Abstract
Background: Hepatocellular Carcinoma is the third most common cause of cancer related death worldwide, often
diagnosed by measuring serum AFP; a poor performance stand-alone biomarker. With the aim of improving on this, our
study focuses on plasma proteins identified by Mass Spectrometry in order to investigate and validate differences seen in
the respective proteomes of controls and subjects with LC and HCC.
Methods: Mass Spectrometry analysis using liquid chromatography electro spray ionization quadrupole time-of-flight was
conducted on 339 subjects using a pooled expression profiling approach. ELISA assays were performed on four significantly
differentially expressed proteins to validate their expression profiles in subjects from the Gambia and a pilot group from
Nigeria. Results from this were collated for statistical multiplexing using logistic regression analysis.
Results: Twenty-six proteins were identified as differentially expressed between the three subject groups. Direct
measurements of four; hemopexin, alpha-1-antitrypsin, apolipoprotein A1 and complement component 3 confirmed their
change in abundance in LC and HCC versus control patients. These trends were independently replicated in the pilot
validation subjects from Nigeria. The statistical multiplexing of these proteins demonstrated performance comparable to or
greater than ALT in identifying liver cirrhosis or carcinogenesis. This exercise also proposed preliminary cut offs with
achievable sensitivity, specificity and AUC statistics greater than reported AFP averages.
Conclusions: The validated changes of expression in these proteins have the potential for development into high-
performance tests usable in the diagnosis and or monitoring of HCC and LC patients. The identification of sustained
expression trends strengthens the suggestion of these four proteins as worthy candidates for further investigation in the
context of liver disease. The statistical combinations also provide a novel inroad of analyses able to propose definitive cut-
offs and combinations for evaluation of performance.
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Introduction
Hepatocellular carcinoma (HCC) accounts for 85–90% of all
tumours emerging from the liver in high incidence areas such as
Asia, Sub-Saharan Africa and parts of Eastern Europe, and
between 70–75% of cases in lower incidence regions. It is the fifth
most common cause of cancer related mortality worldwide for
males and seventh for females [1]. The main reason for the
disproportionate spread of HCC is attributable to the prevalence
of its major risk factors, that is, chronic infection with the Hepatitis
B Virus (HBV), Hepatitis C Virus (HCV) [2] and exposure to
Aflatoxin B1 (AFB1) [3] which exist in the developing world. It has
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a poor prognosis, making it the overall third highest cause of
cancer related mortality worldwide [4]. In a global survey
overseen by the World Health Organisation (WHO), it was
reported that there were approximately 598,000 deaths per
annum (pa) attributable to Liver Cancer [5]. One of the key
reasons for this is the lack of a low cost, reliable early diagnostic
and screening test, useable in the developing world where access to
high performance compensatory diagnostic aids are severely
limited. The lack of viable and affordable treatment options in
the developing world is also a significant contributing factor to the
poor prognosis of this condition.
Primary HCC is a complex multistep disease, which arises from
a myriad of environmental, host genetic and viral factors. Up to
10% of individuals who become infected with the HBV will be
unable to clear it and become chronic carriers. From this, a
fraction will develop HCC, with or without liver cirrhosis (LC) [6]
with a fraction of them not displaying viral antigens in their sera
(occult hepatitis) [7]. These observations support suggestions that
HBV is itself a direct trigger for HCC as it has been shown to
incorporate into host Deoxyribonucleic Acid (DNA) in up to 80%
of cases [8–10]. This is in contrast to HCV induced HCC for
which strong evidence suggestive of direct viral effects has been
difficult to come by [11,12]. AFB1, is another major causative
element linked to HCC and is produced by the fungi aspergillus
flavus contaminating poorly stored grains and nuts. In populations
with large exposure to this toxin, research shows the risk of HCC
development to be in direct proportion to the amount of aflatoxin
ingested [13,14]. This is especially highlighted in a Chinese study
showing the relative risk of HCC development as 3.4 in individuals
exposed to aflatoxin and 7.3 in those chronically infected with
HBV. In patients with both factors present, the relative risk of
HCC development rose significantly to 59.4 [3,15]. As HCC is a
multifactorial disease, the combination of chronic viral infection
and ingestion of the toxin work synergistically to increase the risk
of disease development.
Mass spectrometry (MS) and proteomics approaches have been
used to propose a growing list of biomarker candidates for
diagnostic and prognostic use in HCC as reviewed in recent
publications [16,17]. For instance, studies on HCC tissue [18,19]
and serum [20,21] have revealed a number of molecular
candidates that are currently at various stages of early clinical
validation. To date, however, AFP is the main non-invasive
clinical marker used in the diagnosis and therapeutic monitoring of
this disease, despite its limited specificity and sensitivity [22,23].
To counter this, a comprehensive study using plasma samples from
HCC & HBV endemic areas was launched, setting out to use
proteomic fingerprinting methods to identify highly sensitive and
specific biomarker candidates of greater performance than AFP.
Twenty-six differentially expressed proteins were identified from
discovery MS experiments with six of these further validated in
individual subject plasma and four displaying results suggestive of
their plausibility as novel biomarker candidates for HCC. To
develop shortlisted protein biomarker candidates and confirm
observed differences, independent method and subject validations
were conducted and the results incorporated into extensive
statistical analyses. This work represents the first extensive protein
biomarker study conducted on West African cohorts.
Methods
Ethics Statement
All subjects recruited into the GLCS gave written informed
consent prior to inclusion. Written informed consent was also
provided by all JUTH subjects. Final approval and authorization
for use of the Nigerian samples in research experiments was given
by the research and ethics committee of the University of Jos.
The overall ‘Biomarker Discovery in West African populations’
study proposal was approved by the joint Gambia Government/
MRC Unit and London School of Hygiene and Tropical
Medicine Scientific Coordinating and Ethics Committees (SCC
& Ethics Committee Approval # 1154).
Both subject populations were recruited in concordance with
the ethical guidelines presented in the Declaration of Helsinki.
Study Groups
Two distinct plasma sample sets were used in these investiga-
tions, one recruited from the Gambia; the primary source of
samples for this study and the second from Nigeria; used as a
regional pilot validation cohort. Briefly, the Gambia Liver Cancer
Study (GLCS) samples were collected as part of a five-year liver
cancer case-control study with subjects recruited from three major
healthcare providers in the Gambia; Royal Victoria Teaching
Hospital (RVTH), Bansang Hospital and the Medical Research
Council (MRC) Unit, Fajara. Controls as well as HCC and LC
cases were recruited from all three study sites.
The Nigerian samples were sourced from the Jos University
Teaching Hospital (JUTH) by regional collaborators in a study
overseen by colleagues at Imperial University, London.
GLCS Subject Selection Method & Diagnosis
The GLCS population consists of subjects who were referred to
these centres by local Physicians after displaying signs of liver
disease as well as those who were actively sought by field worker
surveillance of wards and clinics. Eligible individuals were
approached regarding the study and those who were willing gave
informed consent to be included (figure S1). Subjects were bled in
EDTA tubes and in the urban health facilities had their blood
samples sent to the on site Serology lab for immediate separation
followed by storage at -20uC for working samples and 280uC for
all remaining aliquots. The samples from Bansang Hospital were
separated immediately following bleeding and frozen at280uC on
site pending transport on dry ice to the MRC Serology Lab in
Fajara. Working aliquots were taken for lab analyses, which were
used to profile recruited subjects as controls, LC or HCC cases
based on clinical examination, AFP measurement, ultrasonogra-
phy and liver biopsy. The ICD 10 staging standard was applied to
HCC cases that had liver biopsies performed but this was not
taken into consideration when pooling due to the small fraction of
overall HCC cases that had confirmatory liver biopsies done. An
ultrasound (US) scoring system [24,25] was used in the diagnosis of
LC & HCC. This was based on ultrasonographic examinations of
the liver surface, parenchyma, vascular structure and spleen
compared against the gold standard of liver biopsy. In subjects that
have developed LC from chronic HBV infection; sensitivity and
specificity values of 77.8% and 92.5% respectively have been
attained. Approximately 24% of the subjects diagnosed as having
HCC in the GLCS population underwent a liver biopsy (table 1).
Scientific and Ethical approvals (MRC Scientific Coordinating
Committee No. 1154) were granted for 339 single plasma aliquots
of 0.5-1ml to be removed from the frozen archives for utilization in
this study. These formed a nested selection of case-control samples
from the full GLCS cohort. The nested population selection was
based on statistics estimating the minimum subjects per category
that would allow for significant differences in protein abundance to
be identified. The GLCS subjects were not tested for any viral
infections aside from HBV and HCV.
Label-Free Quantitative MS in HCC
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JUTH Subject Selection & Diagnosis
The ethics committee at JUTH in Plateau state, Nigeria
approved the study proposal allowing for sample collection to be
completed. Eligible individuals were consented and had their
blood collected into plasma EDTA tubes. In total, plasma aliquots
for 55 subjects (table 2) were donated by the Taylor-Robinson
group at Imperial [26] for validation experiments with these
classified as either Nigerian healthy controls (NN), Nigerian
Asymptomatic Carriers (NASC), Nigerian cirrhotics (NCirr) or
Nigerian HCCs (NHCC). The categorizations were based on tests
for HBV, HCV and Human Immunodeficiency virus (HIV) virus
status, AFP, biochemical liver indices, US, or Computed
Tomography (CT), endoscopy and or liver biopsy.
Subjects who tested negative for the hepatitis B surface antigen
(HBsAg), HCV antibody as well as HIV and had results not
indicative of liver disease from biochemical assays for AFP,
creatinine, urea, Alanine aminotransferase (ALT), alkaline phos-
phatase, and total bilirubin, were taken as healthy controls.
Asymptomatic carrier subjects were identified as those positive
only for HBsAg with no evidence of cirrhosis following liver biopsy
(conducted on 80% of NASC group). Those without biopsy had
US done which showed no evidence of early stage LC. The NCirr
group within this population were all HBsAg positive with
evidence of cirrhosis seen during US as portal hypertension. Only
one subject had their LC diagnosis confirmed by liver biopsy. The
HCC group had a .95% HBV positive rate with the clinical
diagnosis of HCC based on AFP, US, CT and for one subject,
liver biopsy.
The HCCs were assessed using the Okuda staging system [27]
with all of them identified as Okuda stage II or higher.
GLCS Sample Pooling for Label Free MS
Suspected aetiology of liver disease and age were considered as
the basis for stratifying and pooling samples. Pooling subjects by
age and disease categorization was opted for in the end as it
provided not only more balanced sample numbers for the nine
sub-groups but also allowed for the grouping of individuals with
expected similar levels of basal liver functionality. Sample
collection site was not taken into consideration when pooling. As
a first step, 20 ml of plasma was taken from GLCS subjects in each
age and disease category (figure S2) and pooled together in order
to allow for the identification of robust markers not subject to
individual variations. From this, 200 ml of pooled plasma was
taken forth into the IgG and albumin depletions and downstream
protocols as described below.
T2 Depletion, Protein Quantitation, Off-gel Fractionation
& Gel Viewing
The nine sample pools from the GLCS (figure S2) were each
subjected to top 2 depletion of albumin and IgG [28–30].
Representative aliquots were taken from each depleted pool and
subject to a protein quantitation assay using the EZQ Protein
Quantitation Kit as per manufacturer’s instructions.
Isoelectric focusing (OFF-GEL Fractionator, 3100 Agilent) into 24
fractions was performed on high-resolution pH 3–10 strips as per
Table 1. Summary of key clinical parameters in GLCS subject population.
Variable Control No. Control % LC No. LC % HCC No. HCC %
Biopsy n/a n/a 5 5.1 29 24.2
Clinica Exam 120 100 99 100 120 100
Ultrasound n/a n/a 99 100 120 100
AFP.100 ng/ml 0 0 20 of 95 tested 21.1 106 88.3
Mean ALT (IU/L) 6.58 n/a 12.4 n/a 14.3 n/a
Mean AST (IU/L) 19.3 n/a 64.5 n/a 158.4 n/a
ALT.56 IU/L 1 94.2 tested 0 92.3 tested 4 92.5 tested
AST.40 IU/L 8 93.3 tested 46 94.0 tested 83 94.2 tested
Male 84 70 63 63.6 92 76.7
Female 36 30 36 36.4 28 23.3
Age (mean) 44.4 n/a 43.7 n/a 49.1 n/a
HbsAg Positive 10of 119 tested 8.4 54 of 99 tested 54.5 65 of 117 tested 55.6
Tp53 Mut Positive 5 of 113 tested 4.4 11 of 89 tested 12.4 38 of 105 tested 36.2
E Antigen Positive 0 of 10 positive 0 13 of 41 tested 31.7 12 of 53 tested 22.6
HCV Positive 7 of 120 tested 5.8 14 of 97 tested 14.4 38 of 120 tested 31.7
doi:10.1371/journal.pone.0068381.t001
Table 2. Summary of key clinical parameters in JUTH subject
population.
Variable NN NCLD NCirr NHCC
Biopsy (%) 0 77.7 16.7 4.8
Clinica Exam (No.) 10 18 6 21
Ultrasound (%) 100 – 83.3 100
AFP.100 ng/ml (%) 0 0 16.7 80.9
Mean ALT (IU/L) 22.8 29.6 42 73.3
ALT.56 IU/L (No.) 0 1 2 8
Male (%) 50 72.2 83.3 61.9
Female (%) 50 27.8 16.7 38.1
Mean Age (years) 41 38.1 39.2 47.7
HbsAg Positive (%) 0 100 100 90.5
HCV Positive (%) 0 0 0 4.8
doi:10.1371/journal.pone.0068381.t002
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manufacturer’s protocol. For comparative purposes, aliquots from
all 24 off-gel fractions were separated by Sodium Dodecyl
Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) using
a 4–12% Criterion precast Biorad system run at 200 V for 1 hour.
The gels were fixed in 40% Methanol (MeOH) and 10% acetic
acid (AA) then stained overnight with SYPRO Ruby. A destain
was conducted the next day with 10% MeOH and 7% AA. The
gel images were viewed on a UV transilluminator (AutoChemi
System) with image acquisition using the LabWorks 4.6 software.
The gel images were compared for all 24 fractions and three
disease groups and used to determine which fractions would be
taken forward for analysis by MS. The chosen fractions are
highlighted in figure 1A and were primarily picked based on the
amount of protein material present, absence of an overwhelmingly
abundant protein band and lane uniformity across the respective
age groups.
Protein Precipitation, Digestion, Desalting & MS Analysis
The seven selected off-gel fractions were taken forth for
purification by MeOH-chloroform precipitation of proteins [31].
The obtained pellets were digested and desalted as previously
described [32]. The resultant purified peptides were evaporated in
a vacuum centrifuge, frozen at280 C and resuspended in 50 ml of
solution A (97.9% H2O, 2% Acetonitrile (ACN) & 0.1% Formic
Acid (FA)) on the day of analysis.
The samples generated from this extensive workflow were
analysed by nano-ultraperformance liquid chromatograpy electro-
spray ionization (nUPLCTM ESI) MS/MS in triplicate on a 75 mm
inner diameter 25 cm length C18 nano-AcquityTM UPLCTM
column coupled to a Quadrupole-Time Of Flight (Q-TOF)
premier mass spectrometer (Waters), with 1.7 mm particle size
on a 90 minute gradient of 2–45% solution B (19.9% H2O, 80%
ACN and 0.1% FA). Data acquisition was performed in high-
definition MSE mode which utilizes high and low collision energy
switching, every 1.5 seconds [33].
Data Analysis and Quantitation
Data processing including deisotoping and deconvolution was
performed using the Protein Lynx Global Server software (PLGS
v2.2.5, Waters). MS/MS spectra were reconstructed by combin-
ing all precursor and fragment masses with identical retention
times. The mass accuracy of the raw data was corrected using
Glu-fibrinopeptide (200 fmol/ml; 700 nl/min flow rate;
785.8426 Da [M +2H]2+) that was infused into the mass
spectrometer as a lock mass during analysis (every 30 seconds).
Peptides and regarding proteins were identified by searching the
peak lists against a UniProt/SwissProt database [version
2009.04.23; 19713 human sequence entries] using the following
parameters: Minimum fragment ion matches per peptide: 3;
minimum fragment ion matches per protein: 7; minimum
Figure 1. Quality control of fractionation for MS analysis. (A) Representative SDS-PAGE gel analysis of isoelectric focussing (IEF) fractions from
each disease group following IgG & albumin depletion and off-gel fractionation of subject pools. Visualisation was performed with Sypro Ruby Red
staining showing healthy control (Con, left panel), cirrhosis (middle panel) and hepatocellular carcinoma (HCC, right panel). (B) Natural log
distribution plots of proteins showing their expression changes (ln ratio) for non-liver ailment controls versus HCC and liver cirrhosis cases.
doi:10.1371/journal.pone.0068381.g001
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peptide matches per protein: 1; maximum protein mass:
250000 Da; primary digest reagent: trypsin; missed cleavages:
1; fixed modifications: Carbamidomethyl (C); variable modifi-
cations: Oxidation (M). All protein hits that were identified with
a confidence score of .95% were included in the quantitative
analyses. Identical peptides from each triplicate set per sample
were clustered based on mass precision (,10 ppm, typically ca
5 ppm) and a retention time tolerance of ,0.25 min using the
clustering software included in PLGS v2.3. If two or more
distinct proteins shared an identical peptide but were found to
be regulated differently, then the quantitation algorithm did not
include the peptide in question. In order to allow for this,
peptide probabilities are always softened by the PLGS software
slightly prior to quantitation. Because of this, the contributions
from peptides with even 100% probability of presence were
suppressed in order to avoid potential errors in quantitation.
Normalisation was performed using the PLGS ‘‘auto-normali-
zation’’ function. The statistical significance of relative expres-
sion ratios was calculated using a Monte-Carlo algorithm and
expressed as p,0.05 for down-regulated and 12p.0.95 for up-
regulated proteins, respectively. Only proteins that were
identified in two out of three replicate analysis runs were
selected for further analysis (replicate filter two). To simplify
data analysis, multiple regulation factors obtained for one
unique protein detected in distinct fractions had to be reduced
to a single value. We did not consider multiplicate protein
entries that had controversial regulation values throughout
different fractions. For multiplicates that showed a common
trend for all detected data points, the minimal regulation factor
detected was chosen. A list of differentially expressed proteins
was also imported into the Ingenuity Pathway Analysis (IPA)
software, and the Biomarker discovery tool was consulted for
the short-listing of proteins as potential marker candidates
(table 3). The decision for which shortlisted markers to take
forth for extensive, individual subject based validation was
dependent on literature reports of the proteins in relation to
HCC, commercial kit and antibody availability as well as
representation of various protein families.
ELISA Assays
Enzyme linked immunosorbent assay (ELISA) based measure-
ments were carried out using commercial kits for the four proteins;
a-1-antitrypsin (a1AT), apolipoprotein A1 (Apo A1), hemopexin
(HPX), (Immunology Consultants Laboratory, Portland, OR USA) and
complement component 3 (CC3) (Abnova, Taiwan) according to
manufacturers instructions. All the assays were optimised and were
used at the following dilution factors: a1AT at 1:50,000; Apo A1 at
1:20,000, HPX at 1:30,000 and CC3 at 1:400.
Absorbance measurements were taken at 450 nm and a 4-
parameter logistic regression standard curve generated to extrap-
olate select protein levels in individual samples, taking into account
the respective dilution factors.
Protein Level Extrapolation & ROC Curves
To determine the diagnostic ability of these four proteins, the
statistical software Graph Pad Prism (version 5) was used to generate
Receiver Operator Characteristic (ROC) curves. The area under
these ROC’s is well recognised as a measure of diagnostic ability
for biomarkers [34]. All the background subtracted duplicate
measurements from the known standard and unknown sample
readouts were exported to Graph Pad Prism. The mean of the
duplicate measurements for each subject was taken and Log10
transformed followed by the performance of a nonlinear regression
sigmoidal dose response analysis [35]. This step extrapolated
protein concentrations for the unknown samples. The antilog (10x)
of the obtained values was then calculated followed by a
multiplication by the dilution factor in order to obtain the
accurate protein levels. ROC curves were generated on the same
software by listing the measured protein levels in any two-subject
groups under comparison.
AUC Generation for Selecting Multiplexing Candidates
For statistical multiplexing of candidate markers; the list of
subjects used was curated to ensure that all the cases and controls
included had measurements of a full panel of the biomarker
candidates plus ALT. ROC curve comparisons and statistics were
conducted on this population using the SAS statistical program
(SAS 9.2, SAS Institute Inc., North Carolina, USA). For each putative
biomarker, ROC curves were plotted and Area Under Curve
(AUC) values calculated along with their associated 95%
Confidence Intervals (CI) and Standard Error of the Mean
(SEM) using the PROC LOGISTIC function and %PLOTROC
macro sourced from SAS Institute website (http://support.sas.
com/kb/25/018.html). Comparisons of AUC values were con-
ducted using the %ROC macro downloaded from http://
support.sas.com/kb/25/017.html.
Biomarker Combinations at Specified Cut-offs
For each of the protein combinations that demonstrated greater
discriminatory power than ALT, optimal cut-offs were calculated
based on the maximum likelihood ratio associated with the highest
achievable balance in sensitivity and specificity. These indices were
calculated for ALT, a1AT, Apo A1, CC3 and HPX on a subset of
the GLCS populations using Graph Pad Prism. To further
elucidate these results, the cut-offs were applied to the three
subject categories, to see what levels of sensitivity and specificity
were attainable. Binary combinations based on the ‘‘AND’’ and
‘‘OR’’ methodologies were analysed and resultant sensitivity and
specificity indices tabulated. In these binary combinations ‘‘AND’’
and ‘‘OR’’ were defined as follows: ‘‘AND’’ meant that only a
positive result on both tests was considered positive and ‘‘OR’’ that
only negative results on both tests was considered negative.
Results
Main Causative Factors for Chronic Liver Disease
Represented in GLCS Population in a Condition-specific
Pattern
The GLCS consists of well-defined patient groups representing
the main causative factors of Chronic Liver Disease (CLD); HBV,
HCV and or AFB1 exposure. In the control group the HBsAg
positive rate was measured as 8.4% with none of these individuals
showing ‘e’ Antigen positivity, a marker for active viral replication.
5.8% of the 120 controls were HCV antibody positive. In the LC
group, 14.4% of patients were HCV antibody positive, 54.5%
HBsAg positive and from these 31.7% showed the presence of the
HBV ‘e’ antigen. In the HCC sub-group, the HCV positive rate
was found to be 31.7%, HBsAg carriage stood at 55.6% and the
amount of ‘e’ antigen positive individuals amongst them at 22.6%.
The presence of Single Nucleotide Polymorphisms in the p53
gene, used as a marker for aflatoxin exposure [36] were also
investigated in the GLCS subjects using Restriction Fragment
Length Polymorphism Polymerase Chain Reaction and this
showed the presence of at least one mutation in 4.4% of controls,
12.4% of LC’s and 36.2% of subjects diagnosed with HCC.
Almost all the point mutations detected were at the codon 249
(table 1) [37].
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Label-free Quantitation Identifies Differentially Expressed
Proteins in Plasma between LC, HCC and Control
Subjects from GLCS
The levels of protein present in each of the nine pools were
found to be of the same order of magnitude (data not shown) thus
providing a similar baseline for preparative isoelectric focussing.
SDS-PAGE analysis demonstrated fraction-by-fraction profiles,
which appeared to be similar between the different disease and
healthy control groups with no presence of predominating protein
bands. Seven of the total twenty-four isoelectrically focused
fractions containing the majority of protein material were
subjected to in-solution trypsin digestion and analysed by Q-
TOF MSE. This yielded 1307 unique protein identifications for
the combined 7 processed fractions, with the highest number of
protein identifications made at the lanes corresponding approx-
imately to pH 5.5–6.5; (fractions 13, 14 and 15– figure 1A). These
results include proteins with condition-specific changes in expres-
sion ratios as high as 21 fold (fraction 13) and 22 fold (fraction 15)
as well as other proteins exclusively found in specific disease states.
Stringent Filtering Results in the Identification of 26
Differentially Expressed Proteins from the GLCS
Population
A set of 21 extracellular and plasma proteins were identified and
shortlisted following streamlined filtering as described in the
methods section as differentially expressed in HCC subjects versus
Table 3. Differentially expressed proteins in plasma from controls, LC and HCC subjects identified by quantitative MS.
Differentially Expressed Proteins Fraction Swissprot ID. Score
Seq.
Cov. %
¡ of
Peptides HCC vs CON Ratio CON vs. LC Ratio
alpha-2-macroglobulin 14 P01023 1385.68 67.5 83 1.04 (1), 1.32 (1), 1.04 (0.98) HCC vs. CON
apolipoprotein E 14 P02649 391.2 71.3 27 1.42 (1), 1.60 (1), 1.40 (1) 0.92 (0.01), 0.74 (0), 0.76
(0)
complement component
4 binding protein,a
14 P04003 91.8 40.4 20 1.07 (0.97), 1.68 (1), 0.96 (1) 0.97 (0.3), 0.84 (0), 0.90
(0.05)
complement factor I 14 P05156 61.02 36.7 20 1.07 (0.8), 1.07 (0.86),
1.04 (0.64)
HCC vs. CON
glutathione peroxidase 3 14 P22352 61.26 42 10 1.27 (1), 1.45 (1), 1.04 (0.65) 0.66 (0), 0.61 (0), 0.72 (0)
apolipoprotein H 15 P02749 49.75 41.4 10 1.04 (0.61), 1.20 (0.97),
1.06 (0.77)
2.39 (1), 1.77 (1), 1.80 (1)
complement component 4B 6 P0C0L5 384.56 17.1 22 1.02 (0.69), 1.68 (1), 1.04 (0.91) 1.30 (1), 1.36 (1), 1.21(1)
Alpha-1-antichymotrypsin 6 P01011 524.43 37.6 13 1.65 (1), 1.34 (1), 1.28 (1) 0.84 (0), 0.51 (0), 0.96
(0.07)
carboxypeptidase N, polypeptide 2 4 P22792 206.51 38 14 1.19 (0.93), 1.05 (0.76),
1.06 (0.71)
HCC vs. CON
leucine-rich alpha-2-glycoprotein 1 4 P02750 170.54 49.6 15 1.86 (1), 1.40 (1), 1.11 (0.92) 0.51(0), 0.84 (0), 0.79 (0)
complement component 3 14 P01024 569.1 52.1 79 0.88 (0), 0.84 (0), 0.78 (0) 1.46 (1), 1.56 (1), 1.19 (1)
apolipoprotein A-I 15 P02647 110.79 65.9 17 0.55 (0), 0.68 (0), 0.66 (0) 1.52 (1), 1.23 (0.99), 1.73
(1)
complement factor H 15 P08603 566.61 62.5 63 0.90 (0), 0.69 (0), 0.90 (0) 1.15 (1), 1.42 (1), 1.25 (1)
haptoglobin-related protein 15 P00739 191.45 59.2 21 0.64 (0), 0.65 (0), 0.99 (0.41) 1.43 (1), 1.38 (1), 1.21(1)
hemopexin 13 P02790 333.07 59.3 23 0.56 (0), 0.45 (0), 0.68 (0) 1.57 (1), 1.92 (1), 1.60(1)
alpha-1-microglobulin/
bikunin precursor
6 P02760 158.24 31 7 0.75 (0), 0.71 (0), 0.73 (0) 1.39 (1), 1.27 (1), 1.42 (1)
paraoxonase 1 6 P27169 146.28 39.4 9 0.54 (0), 0.81 (0.07), 0.54 (0) 1.27 (1), 1.52 (0.99), 1.78
(1)
clusterin 4 P10909 102.59 39.2 17 0.76 (0), 0.48 (0), 0.52 (0) 1.52 (1), 1.67 (1), 2.30 (1)
complement component 4A 15 P0C0L4 82.92 19.6 28 CON vs. LC 1.28 (1), 1.30 (1), 1.22 (1)
haptoglobin 13 P00738 286.29 60.1 22 CON vs. LC 1.54 (1), 1.35 (1), 1.17 (1)
complement factor B 21 P00751 544 52.2 36 CON vs. LC 2.36 (1), 1.97 (1), 1.20 (1)
Alpha-1-antitrypsin 4 P01009 186.57 39.5 14 CON vs. LC 0.39 (0), 0.29 (0), 0.87
(0.21)
caspase 8 13 Q14790 16.81 12.5 7 0.80 (0.1), 0.66 (0.01),
0.93 (0.31)
HCC vs. CON
fibrinogen alpha chain 13 P02671 75.6 27.5 19 0.90 (0.04), 0.84 (0), 0.51 (0) 1.12 (0.96), 1.11 (0.93), 1.52
(1)
amyloid P component, serum 13 P02743 94.24 36.8 10 CON vs. LC 2.83 (1), 1.84 (1) 1.40 (1)
CD5 molecule-like 12 O43866 650.63 61.7 23 1.17 (1), 1.32 (1), 1.19 (1) 0.61 (0), 0.54 (0), 0.53 (0)
Format of tabulated results is = Ratio of compared values (p-value pertaining to it) in the order Young, Middle, Old Up regulated proteins are those with ratios.1. Cut
off for significance = 0.95 (12p) Down regulated proteins are those with ratios ,1. Cut off for significance = 0.05 (120.95).
doi:10.1371/journal.pone.0068381.t003
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individuals with no evidence of liver related ailments. In workflows
comparing controls and subjects with active liver cirrhosis, 22
proteins were shortlisted as possible biomarker candidates. The
overlap between the two groups means that a total of 26 proteins
(table 3) were with the GLCS population found to have condition-
specific signatures over the spectrum of non-liver related ailments
to the development of liver cancer. Of these 26, alpha-2-
macroglobulin, complement factor I, carboxypeptidase N (poly-
peptide 2) and caspase 8 showed expression patterns suggesting
their diagnostic potential for HCC only, whilst the MSE data for
complement component 4A, haptoglobin, complement factor B,
a1AT and serum amyloid p suggested the changes in these
proteins as unique to subjects with LC. As the diagnosis of early
stage HCC in a cirrhotic liver is of significant clinical importance,
all validated proteins, regardless of which progressive condition
they seemed significant or unique for, were measured in all three
sub-groups.
Alpha-1-Antitrypsin, Complement Component 3,
Apolipoprotein A1 and Hemopexin show same
Expression Trends in MS and ELISA based Analysis
Individual GLCS subject validation by ELISA allowed for direct
measurements of target proteins in plasma in order to verify the
expression changes suggested by MS. To achieve this, we selected
four shortlisted proteins based on representation of various protein
families interpreted as suggestive of their involvement in different
pathways, implications in literature and availability of quality
commercial antibody based methods for direct measurements and
took them forth for more comprehensive validation. Plots showing
the relative expression trends for three representative peptides in
triplicate allocated to a1AT, CC3, Apo A1 and HPX identified
with high scores in all three disease categories were selected and
compared (figures 2E & 3 B–E). Without exception, the trends in
expression seen at the peptide level, between the three disease
groups were identical to those seen in direct measurement of these
four proteins in individual subjects by ELISA.
ELISA Validation of Four Markers Identified by Label-free
Proteomics Suggests Diagnostic Potential
The four proteins selected for validation were measured in
individual GLCS subject plasma across the three disease
groupings using ELISA based assays (figure 3). Measurement
of a1AT showed a net increase in the proteins overall level with
the most significant change observed between mean amounts of
plasma a1AT in the control versus HCC groups; an AUC of
0.8395, calculated by ROC analysis suggests a high discrimi-
natory potential. HPX levels in subject plasma showed an
overall trend of lowered expression in those with active cirrhosis
compared to controls, with a ‘‘bounce back’’ effect seen as the
protein levels are somewhat restored to control levels in the
HCC subjects. The highest reported AUC was for the change
in HPX levels of Con vs. LC; 0.8160. The trend for CC3
expression was similar to that of HPX with its levels dropping
from control to LC and rising again in the presence of a liver
tumour. However with this protein, the biggest observable
difference was seen between cirrhotic and HCC patients with
an AUC of 0.7024. The last protein from our shortlist which
was validated by ELISA was the high density lipoprotein
component, Apo A1. The trend with this candidate was a
significantly lowered expression as patients develop LC and
HCC. The biggest change in expression was observable between
the control and HCC groups with a reported AUC of 0.8341.
The strong suppression in ApoA1 levels seen between controls
and LC subjects also gave a significant AUC reading of 0.7899
(figure 3).
Chronic HBV Infection is Strongly Associated with
Chronic Liver Disease Development in JUTH Subjects
To an even greater degree than that observed in the GLCS,
chronic HBV infection was seen to be strongly associated with the
development of LC and HCC in the subjects from Nigeria. Other
risk factors for HCC and LC development noted from both subject
populations (tables 1 & 2) are being of male sex, increased age,
elevated ALT and AFP levels. A low-lying trend of HCV infection
is also observable in the NHCC group although it is slightly above
the estimated prevalence for West Africa [38]. No assessment of
aflatoxin exposure was conducted in this subject population.
Previously Reported Protein Expression Trends Validated
in a Pilot Population of Independent West African
Subjects
ELISA assays which measured the expression levels of a1AT,
Apo A1, CC3 and HPX in the JUTH subjects, showed trends
consistent with those seen in the GLCS (figures 3 & 4). In the latter
population, a1AT expression was seen to discriminate best
between controls and HCC subjects based on AUC calculations.
A similar trend was seen in the Nigerian subjects which showed
a1AT to give an AUC of 0.7857 (figure 4A.) when comparing
overall expression between control and HCC subjects. This was
marginally lower than that for NCirr vs. NHCC discrimination
with this slight discrepancy in trend likely due to the small number
of cirrhotic patients compared to HCCs within the JUTH subject
group. The marked decline in ApoA1 plasma secretion previously
observed was once again seen, resulting in a peak AUC of 0.7667
between the NN and NHCC groups. Overall, the same trend
witnessed in the Gambian subjects was mirrored in those from the
JUTH with a marked down-regulation of Apo A1 as liver disease
progressed towards hepatocarcinogenesis. The consistency be-
tween the two populations was also maintained for CC3 and HPX
expression with the highest discriminatory potential for the former
seen in the development of HCC from a background of LC. In the
Nigerian subjects, this was seen with a peak AUC of 0.8571. With
HPX, consistent with previous results, levels of expression were
seen to drop in patients with LC and ‘‘bounce back’’ in those with
HCC. The calculated AUC for the development of LC in the
Nigerian subjects suggests excellent discriminatory potential for
this protein with a statistically significant (p.001146) AUC value of
1.000.
Analysis of Test Combinations Suggest HPX, CC3 and
Apo A1 as Superior to ALT in Diagnosing LC
Comparisons of various combinations of the four validated
candidate biomarkers and ALT highlight that HPX, CC3 and
Apo A1 are individually all superior to ALT in discriminating
control and LC cases. HPX in this subject population has been
shown to have an AUC of approximately 0.80 (figure 3A), a value
that is significantly higher than that for ALT when used singly to
distinguish the same two groups; 0.6507 (figure 5). A negligible
boost in diagnostic accuracy from the single use of HPX is seen
when these two markers are combined (table 4) although the
difference between using HPX and HPX & ALT combined does
not reach significance. However, combining ALT and a complex
of HPX & ALT offers similar discriminatory power (AUC 0.7949)
and carries a significant improvement compared to using ALT
alone (p = 0.0095).
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The other two proteins suggested to perform better than ALT in
detecting LC are CC3 and Apo A1, with respective AUC’s of
0.7039 and 0.7638 (data not shown). In both cases, some
discriminatory benefit is indicated by complexing the proteins
with ALT alone although the degree of changes seen are not
significant. When both proteins are complexed with ALT, the
AUC’s obtained improve significantly from that seen with single
ALT measurements.
Analysis of Test Combinations Suggests ALT Combined
with a1AT, Apo A1 or HPX Boosts Discriminatory
Potential in HCC Patients
ALT in the GLCS population shows high performance (AUC
0.8372) in discriminating the control and HCC groups. Despite
this, some benefit is still observed when it is complexed with a1AT
or Apo A1 with upwards shifts in AUC to 0.8723 and 0.8899
respectively (figure 5 C & D). The latter combination of ALT &
Apo A1 results in noteworthy statistics suggesting that the increase
in diagnostic ability conferred by using the two markers in a panel
is significant; p = 0.0183 (table 4).
As has been the trend in all the analyses of this study, the two
groups most difficult to differentiate are those classed as LC and
HCC. From the multiple comparisons performed, two of the
markers demonstrated an improvement from the discriminatory
values seen with ALT alone. HPX on its own did not perform
better than ALT in distinguishing these two groups but when
complexed with ALT demonstrates an AUC of 0.7650. A
marginal increase is also observed for a1AT over single ALT
use but its highest values are attained when used in tandem as seen
in table 4.
Application of Specified Cut-offs to Binary Protein
Combinations Significantly Boosts Diagnostic Ability
The application of defined cut-offs to protein combinations with
superior AUC values to single ALT use primarily highlighted that
the ‘‘OR’’ criteria for test design may be superior in offering
balanced sensitivity and specificity values for diagnosis. These
results also suggest that higher individual sensitivity or specificity
values are attainable with the ‘‘AND’’ criterion.
ALT combined with CC3 in discriminating CON and LC
subjects; HPX for LC and HCC and ApoA1 in CON and HCC
Figure 2. Identification of differentially expressed proteins in plasma from control, cirrhosis and HCC subjects by label-free
quantitative MS. (A–D) Sequence coverage levels for differentially expressed proteins identified and selected for independent validation.
Underlined sequences represent tryptic peptide fragments identified by MSE. (E) Relative expression plots of robustly identified peptides uniquely
attributed to either ApoA1, a1AT, CC3 or HPX and comparing their relative mass peak intensities across the three different disease groups.
doi:10.1371/journal.pone.0068381.g002
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discrimination showed upward shifts in AUC with significant p
values, though the significance level for the first comparison was
borderline (p,0.0687). When specified cut-offs were used,
accurate subject assignments between the CON and HCC groups
with the following criteria – ‘‘ALT of .10.50 IU/ml OR
ApoA1.0.7673 mg/ml’’ had respective sensitivity and specificity
values of 82.5% and 74.5%. HPX & ALT combined with the same
OR criterion at cut-offs of HPX.2.701 mg/ml and AL-
T.13.50 IU/ml in the LC and HCC categories had high
sensitivity, but poorer specificity; 97.50% and 51.67% respectively
(Table S1A & C).
In the use of ALT and CC3 together for discerning the CON
and LC groups, the ‘‘OR’’ command again showed a greater
balance in achievable sensitivity and specificity; 85.0% & 57.5%,
respectively than using the cut-offs of ALT.9.5 IU/ml and
CC3,0.9579 mg/ml with the ‘‘AND’’ command. The latter
produced results which skewed the balance towards poor
sensitivity (18.33%) but high specificity (93.62%) (Table S1b).
Discussion
As with many solid tumours for which high performance non-
invasive diagnostic tools are lacking, the identification of reliable
predictive markers for HCC is of prime importance. The greatest
burden of this disease and its major causative factors exist in the
developing world where many of the sophisticated imaging tools
used to compensate for the insufficient performance of AFP are
not widely available. The liver, as the main site of plasma protein
synthesis and metabolic activities such as detoxification and
storage is a central organ in the body. Measurement of plasma
proteins, even the highly abundant acute phase proteins, most of
which are processed by or derived from it, can as such provide
deep and relevant insight into how specific changes in key proteins
may be relevant in the development of HCC.
To address the issue of heterogeneity and sample selection
bias which has the potential to impact all human studies, a
large population of 339 subjects was selected and pooled as to
average out individual differences and highlight more general
overarching trends. Suspected aetiology of liver disease and age
were considered as the basis for stratifying and pooling samples
but the latter was chosen as it offered a more even distribution
of subjects, per sub-group and would allow for a more distinct
separation strategy, as many of the subjects were positive for
more than one of the key aetiological factors (HBV, HCV or
p53 mutation). There is also a growing body of work which
suggests that there are age related changes which occur in the
liver resulting in its reduced volume, decline in metabolism of
certain drugs, changes in protein expression and lowered
hepatobiliary functions. Other more subtle changes have also
been linked to the ageing liver, particularly at the DNA level
and are considered to result in lowered rates of DNA repair,
which may have direct implications in virus, or toxin induced
mutations that lead to hepatocarcinogenesis [39,40]. The
Figure 3. Protein marker validation by ELISA in GLCS. (A) Data of sample numbers tested per protein reported with AUC’s, confidence
intervals and associated p values. (B–E) Dot plots highlighting trends in protein level expression across controls and subjects with LC or HCC for
a1AT, Apo A1, CC3 and HPX.
doi:10.1371/journal.pone.0068381.g003
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pooling of samples by age within the distinct disease categories
encouraged the extraction of proteins whose secretory and
regulatory signatures are not age dependent. Candidates robust
enough to remain highlighted through this process stand at
some advantage, as the observation of uniform trends across the
three age ranges suggest they will likely be usable at all levels of
healthy or disease liver function.
Direct measurement of Apo A1 by ELISA in individual GLCS
subjects (figure 3B) confirms the changes in protein abundance
predicted by MS and shows the protein to be severely down-
regulated with impaired liver function as determined by deterio-
rating liver enzyme readings (table 1). This finding suggests that
changes in its secretory pathway are altered during disease
progression. Other studies [41,42] corroborate these findings with
one group proposing the lowered expression of Apo A1 in subjects
with confirmed HCC as a prognostic marker for portal vein
metastases [43]. a1AT by comparison shows a reverse trend with
increasing circulatory plasma levels as liver function wanes. The
serpin protease and its precursor fragments have been implicated
in numerous LC and HCC related studies as plausible biomarker
candidates. One such study linked a1AT expression to treatment
efficiency following Transarterial Chemoembolization (TACE)
[44]. Kang and colleagues in a LC-MS based investigative
screening exercise looking at sera from 9 histologically confirmed
HCC’s compared with LC subjects reported a 10-fold change in
a1AT expression between the two groups [45]. a1AT as a major
plasma glycoprotein with three reported glycosylation sites [46]
has had its core fucosylated form [47] also specifically shown to
have altered modification patterns that are highly sensitive and
specific to HCC and or LC [48].
Direct ELISA measurements of CC3 and HPX in individual
subjects show a dip in expression with the development of LC and
a restoration to healthy levels of protein expression within the
HCC group. This pattern may be indicative of a loss of liver
functionality with LC due to a larger volume of the liver being
affected, whereas hepatocarcinogenesis on a liver without a
background of extensive cirrhosis could have greater overall
functionality and hence still be able to produce key proteins at
customary levels.
The identification of these two proteins as strongly associated
with chronic liver disease (CLD) is consistent with other studies
which demonstrate that CC3 levels or those of its processed units
alter significantly between individuals with HCC in comparison to
healthy controls or CLD sufferers [42,49,50]. MALDI-TOF MS
profiling of serum from 78 HCC cases matched with 72 cancer
free controls from Egypt identified six candidate markers showing
strong association with HCC, regardless of hepatitis virus status.
One of the panel of six was identified by sequencing as a fragment
of CC3 [51]. A similar study conducted in Japan on HCV
associated HCC versus HCV related CLD without hepatotumor-
igenesis identified the protein fragment demonstrating the most
significant differential expression between the two groups as
belonging to CC3 [52]. Similar reports have been made for our
fourth validation marker; hemopexin. A study, which measured
levels of fucosylated HPX found significantly, elevated quantities
of its expression in a cohort of 229 serum samples from patients
Figure 4. Protein marker validation by ELISA in JUTH. (A) Data of sample numbers tested per protein reported with AUC’s, confidence
intervals and associated p values. (B–E) Dot plots highlighting trends in protein level expression across controls and subjects with Asymptomatic liver
disease, LC or HCC for a1AT, Apo A1, CC3 and HPX.
doi:10.1371/journal.pone.0068381.g004
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with chronic hepatitis, LC, and HCC [53]; a finding that was
previously reported in an earlier publication [54]. A recent study
by Japanese investigators also assessing the clinical utility of serum
fucosylated hemopexin in HCC, LC and chronic hepatitis subjects
concluded that the glycoprotein could be used as a biomarker
potentially indicative of a hypercarcinogenic liver [55].
The trends reported from the quantitative measurements of all
four shortlisted proteins conducted by ELISA in the pilot
Figure 5. ROC Curves for Multiplexed Proteins in GLCS. (A–D) ROC curves demonstrating shifts in discriminatory ability for labeled
comparisons between putative markers and ALT.
doi:10.1371/journal.pone.0068381.g005
Table 4. Statistical summary of combinations of putative marker candidates with routine liver function tests.
Con (n=47) vs. HCC (n=40) AUC SEM 95% CI Comparison(p)
ALT (IU/ml) 0.8372 0.0437 0.7516–0.9228 n/a
ALT_a1AT 0.8723 0.0412 0.7915–0.9513 a1AT vs. ALT_ a1AT p= 0.0765
ALT vs. ALT_ a1AT p= 0.4288
ALT_ApoA1 0.8899 0.0357 0.8199–0.9599 ApoA1 vs. ALT_ ApoA1 p= 0.0183
ALT vs. ALT_ApoA1 p= 0.1379
Con (n=47) vs. LC (n =60)
ALT (IU/ml) 0.6507 0.0532 0.5464–0.7550 n/a
HPX_ALT 0.8014 0.0428 0.7176–0.8852 HPX vs. HPX_ALT p= 0.5871
ALT vs. HPX_ALT p = 0.0095
LC (n =60) vs. HCC (n=40)
ALT (IU/ml) 0.7079 0.0524 0.6053–0.8105 n/a
a1AT_ALT 0.7663 0.0488 0.6707–0.8618 a1AT vs. ALT_ a1AT p= 0.0899
ALT vs. ALT_ a1AT p= 0.2066
doi:10.1371/journal.pone.0068381.t004
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validatory JUTH subjects show expression trends largely identical
to those seen in the Gambian group. These experiments
independently confirm that the secretion of Apo A1 into plasma
is increasingly inhibited during LC and HCC development; a1AT
levels are marginally increased with LC followed by a marked up-
regulation with progression to HCC. CC3 & HPX show
alternative trends to the afore mentioned markers suggesting
them to possess signatures more exploitable for the diagnosis of LC
or HCC from a cirrhotic background than that from a healthy
non-cirrhotic liver. It is worth noting though that the distinction of
the first two groups would be of greatest clinical relevance as up to
80–90% of HCCs have been reported to develop from a
background of LC [56] making it a primary risk factor for HCC
onset. The differences in discriminatory power shown by these
proteins suggest their involvement in alternate pathways; an
implication that could prove particularly useful in their utilization
as part of a panel of multiplexed markers with calculated cut-offs
for diagnoses based on achievable sensitivity and specificity. In
comparing our findings with reports from other studies; specific
alterations in target protein trends may be identified; these will
likely be attributable to the different subject populations under
study, host genetics, dominant aetiological factor associated with
LC and HCC in any given populace as well as the role played by
confounding factors such as aflatoxins. Significant differences in
the trends of expression of biomarker candidates may also be due
to the stringency of case definitions and diagnostic parameters as
well as varying study designs.
In any attempt to identify a viable, high performance biomarker
within a subject population; shortlisted candidates will at some
point have to be compared against contemporary tests in current
clinical use. A major challenge faced in doing this is when these
benchmark assays have been used intrinsically to classify the
various subject groups under study. AFP formed part of the
diagnostic profile of both the GLCS and JUTH subjects – thus
when used in these populations to approximate its diagnostic
ability, the observed AUC was grossly exaggerated. Consequently,
when it came to the utilization of statistical methods to combine
a1AT, Apo A1, CC3 and HPX with more established markers –
an independent indicator of liver health, ALT, had to be
employed. It must be noted however that the measurement of
this enzyme is not irrelevant to the subject of chronic liver disease
diagnosis especially amongst long-term HBV carriers in whom
studies have shown the level of ALT to be associated with elevated
risk of morbidity and poor development of liver health [57,58].
Patients positive for the HBeAg are considered to be at an
advanced risk for HCC development due to its indication of active
viral replication; within this group, rising ALT is also associated
with increased likelihood of seroconversion [59]. A large study
including 3160 participants in Taiwan tried to determine the effect
of ALT in defining HCC risk. After a follow up period of 38,330
person years in which 81 participants developed HCC, it was
concluded that trends in long-term levels of ALT expression was
an independent predictor of HCC development and its regular
monitoring in chronic HBV carriers is of clinical important [60].
In light of these reports, the choice of ALT as a comparative
marker in this investigation may not be ideal but is still useful in
offering insight as to how these four proteins perform in
comparison to current routine clinical indicators of liver disease.
Not much has been reported on the independent diagnostic ability
of AFP, but reports approximate it at 0.70, with at least one
publication showing AUC values as low as ,0.60 when used at a
cut off of 100 ng/ml [61].
The results detailed above highlight the protein combinations
which perform better than the sole use of ALT and AFP
approximation. The shifts seen with the application of calculated
cut-offs depict the fine balance that has to be struck when
combining multiple proteins into a single diagnostic test. No single
approach to this has been universally proposed; rather the logic for
how multiple tests are combined continues to be uniquely tailored
to the complimentary values of the markers under use. To begin to
move these combination methods toward successful application in
real life assays, some synergy will need to be established between
medical researchers who identify and propose candidates and kit
developers with the expertise to design viable pilot assays useable
in the extensive validation of novel test panels.
The attempt made in these investigations to advance differen-
tially expressed proteins from discovery experiments and validate
their expression profiles in a regional subject group with expected
similar aetiology of liver disease is an important step in establishing
the differential expression and robustness of these markers. The
major findings detailed carry the potential for further investiga-
tions helping to characterize how these proposed HCC and LC
biomarkers may perform in non-African chronic liver disease
subjects as well as a more thorough description of possible
mechanisms at play in bringing about the described expression
changes. Such investigations are warranted but will require
extensive resources and expertise as well as collaborations between
international laboratories in order to promote candidates to a
point where they can be strongly proposed for development into
routine laboratory assays.
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